News & Events – Page 3 – Sumitovant

Select Company

March 22, 2022Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
March 07, 2022Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
March 02, 2022Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant
February 25, 2022Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
February 10, 2022Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
February 07, 2022Myovant Sciences to Present at Upcoming Investor Conferences
January 26, 2022Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
January 26, 2022Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
December 20, 2021Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
December 10, 2021Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
« Previous 1 2 3 4 5 … 22 Next »